Aurora 1:1 Drops (Indica)

Phase 2Small molecule

BBC Centre on Substance Use

Aurora 1:1 Drops (Indica) is one of 9 small molecule programs targeting Opioid. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OpioidRecruiting

OpioidPhase 2

Recruiting

Competition

Competitive Landscape

11 competitors in Opioid

#DrugCompanyPhaseTrials

Oxycontin

PProtega

Phase 3

4 2

Epidiolex

Jazz Pharmaceuticals

Phase 2

1 3

Suboxone

Merck & Co.

Phase 3

1 4

Narcan

SScienture

Phase 1

7 5

DOVATO

GSK

Phase 3

1 6

Alfenta

Jazz Pharmaceuticals

Preclinical

1 7

Barhemsys

Tibotec Pharmaceuticals, Ireland

Preclinical

1 8

Imodium

KKenvue Brands

Phase 1

1 9

Aurora 1:1 Drops (Indica)

BBC Centre on Substance Use

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Opioid

NCT05985850

Clinical

Trials by Indication[1]

Opioid1 trial

Evaluating Tetrahydrocannabinol as an Adjunct to Opioid Agonist Therapy

Recruiting·BBC Centre on Substance Use·Phase 2·NCT05985850·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Aurora 1:1 Drops (Indica). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Aurora 1:1 Drops (Indica) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Aurora 1:1 Drops (Indica). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BC Centre on Substance Use company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBC Centre on Substance Use

Aurora 1:1 Drops (Indica)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Opioid1 trial

References

Drug Info

Quick Facts

Related News